C0087111||treatment
C0199176||prevention
C0085083||ovarian hyperstimulation syndrome
C0085083||ovarian hyperstimulation syndrome
C0085083||ovarian hyperstimulation syndrome
C0043210||women
C0087111||treatment
C0872104||assisted reproductive technology
C0282443||review
C1706244||summarize
C0087111||treatment
C0199176||prevention
C0085083||ovarian hyperstimulation syndrome
C0162340||understood
C0078058||vascular endothelial growth factor
C1141639||Human chorionic gonadotropin
C0039869||thought
C0085083||ovarian hyperstimulation syndrome
C0007320||recent case reports
C0066928||anti-Mullerian hormone
C0037083||signalling pathway
C0023395||CD11c
C0019764||HLA-DR
C0011306||dendritic cells
C0021764||interleukins
C0699748||pathogenesis
C0087111||Treatment
C0344211||supportive
C1269815||identifying
C0043210||women
C0871685||clinician
C1268855||GnRH antagonist
C2987634||agonist
C0035168||research
C0871685||Clinicians
C0085083||ovarian hyperstimulation syndrome